Caroline Cassels May 23, 2023 The US Food and Drug Administration (FDA) has approved extended-release injection buprenorphine (Brixadi, Braeburn Inc) for the treatment of moderate to severe opioid use disorder (OUD). The medication comes in two formulations: a weekly and a monthly version. The weekly treatment is indicated in patient who have initiated treatment with a single dose of...